Climb Bio Inc [CLYM] stock prices are up 9.47% to $2.08 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CLYM shares have gain 19.54% over the last week, with a monthly amount glided 15.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on October 13, 2025, and set its price target to $9. On August 15, 2025, Robert W. Baird initiated with an Outperform rating and assigned a price target of $9 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $10 on June 06, 2025. BTIG Research initiated its recommendation with a Buy and recommended $7 as its price target on May 22, 2025. Leerink Partners started tracking with an Outperform rating for this stock on December 02, 2024, and assigned it a price target of $10.
The stock price of Climb Bio Inc [CLYM] has been fluctuating between $1.05 and $3.19 over the past year. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $2.08 at the most recent close of the market.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.23 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9300 points at the first support level, and at 1.7900 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1800, and for the 2nd resistance point, it is at 2.2800.
Ratios To Look Out For
It’s worth pointing out that Climb Bio Inc [NASDAQ:CLYM]’s Current Ratio is 18.38. On the other hand, the Quick Ratio is 18.38, and the Cash Ratio is 3.66.
Transactions by insiders
Recent insider trading involved Brennan Aoife, President and CEO, that happened on Jun 30 ’25 when 20618.0 shares were sold. SVP, Finance & CAO, Pimblett Emily completed a deal on Jun 20 ’25 to sell 1242.0 shares. Meanwhile, SVP, Finance & CAO Pimblett Emily sold 1199.0 shares on Mar 20 ’25.
